Vascular smooth muscle cell apoptosis induced by 7-ketocholesterol was mediated via Ca2+ and inhibited by the calcium channel blocker nifedipine

被引:22
作者
Sasaki, Hidehisa
Watanabe, Fusako
Murano, Takeyoshi
Miyashita, Yoh [1 ]
Shirai, Kohji
机构
[1] Toho Univ, Sch Med, Sakura Hosp, Dept Internal Med, Chiba 2858741, Japan
[2] Toho Univ, Sch Med, Sakura Hosp, Dept Pharm, Chiba 2858741, Japan
[3] Toho Univ, Sch Med, Sakura Hosp, Dept Clin Lab Med, Chiba 2858741, Japan
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2007年 / 56卷 / 03期
关键词
D O I
10.1016/j.metabol.2006.10.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Previous reports indicate that 7-ketocholesterol (7KCHO) induces apoptosis of cultured human vascular smooth muscle cells (SMCs). We hypothesized that calcium channel blockers will inhibit SMC apoptosis induced by 7KCHO because caspase-3 activity is Ca2+ dependent and 7KCHO stimulates caspase-3 and SMC apoptosis. So, the protective effect of the calcium channel blocker nifedipine on SMC apoptosis induced by 7KCHO was investigated. When 7KCHO (50 mu mol/L) was added to SMCs, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate (dUTP)-biotin nick end-labeling was positive. DNA extracted from SMCs exposed to 7KCHO showed a ladder pattern on agarose electrophoresis. In the presence of extracellular Ca2+, the Ca2+ influx, caspase-3 activity, and fragmented DNA also increased in SMCs incubated with 7KCHO dose-dependently. However, in the absence of extracellular Ca2+, no effects of 7KCHO on caspase-3 activity and fragmented DNA were observed. In the presence of nifedipine, the 7KCHO-induced increases in Ca2+ influx, caspase-3 activity, and the amount of fragmented DNA decreased significantly. These results suggest that 7KCHO-induced apoptosis of SMCs is inhibited by calcium channel blockade, and that Ca2+ influx into cells mediated by 7KCHO plays an important role in 7KCHO-induced apoptosis. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:357 / 362
页数:6
相关论文
共 30 条
[1]  
BOISSONNEAULT GA, 1991, P SOC EXP BIOL MED, V196, P338
[2]   EFFECT OF OXYSTEROL-ENRICHED LOW-DENSITY-LIPOPROTEIN ON ENDOTHELIAL BARRIER FUNCTION IN CULTURE - LOW-DENSITY LIPOPROTEINS [J].
BOISSONNEAULT, GA ;
HENNIG, B ;
WANG, Y ;
OUYANG, CM ;
KRAHULIK, K ;
CUNNUP, L ;
OELTGEN, PR .
ANNALS OF NUTRITION AND METABOLISM, 1991, 35 (04) :226-232
[3]   Oxysterols and atherosclerosis [J].
Brown, AJ ;
Jessup, W .
ATHEROSCLEROSIS, 1999, 142 (01) :1-28
[4]   Inhibition by cholesterol oxides of NO release from human vascular endothelial cells [J].
Deckert, V ;
Brunet, A ;
Lantoine, F ;
Lizard, G ;
Millanvoye-van Brussel, E ;
Monier, S ;
Lagrost, L ;
David-Dufilho, M ;
Gambert, P ;
Devynck, MA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (07) :1054-1060
[5]   Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins - Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation [J].
Deckert, V ;
Persegol, L ;
Viens, L ;
Lizard, G ;
Athias, A ;
Lallemant, C ;
Gambert, P ;
Lagrost, L .
CIRCULATION, 1997, 95 (03) :723-731
[6]   Suppression of apoptosis by nitric oxide via inhibition of interleukin-1 beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases [J].
Dimmeler, S ;
Haendeler, J ;
Nehls, M ;
Zeiher, AM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (04) :601-607
[7]   Inhibitory effects of tetrandrine on the serum- and platelet-derived growth factor-BB-induced proliferation of rat aortic smooth muscle cells through inhibition of cell cycle progression, DNA synthesis, ERK1/2 activation and c-fos expression [J].
Fang, LH ;
Zhang, YH ;
Ma, JJ ;
Du, GH ;
Ku, BS ;
Yao, HY ;
Yun, YP ;
Kim, TJ .
ATHEROSCLEROSIS, 2004, 174 (02) :215-223
[8]   CALCIUM-ANTAGONISTS AS ANTIATHEROSCLEROTIC AGENTS [J].
HENRY, PD .
ARTERIOSCLEROSIS, 1990, 10 (06) :963-965
[9]  
Khalfi F, 1998, BIOL PHARM BULL, V21, P109
[10]   NIFEDIPINE - KINETICS AND DYNAMICS IN HEALTHY-SUBJECTS [J].
KLEINBLOESEM, CH ;
VANBRUMMELEN, P ;
VANDELINDE, JA ;
VOOGD, PJ ;
BREIMER, DD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (06) :742-749